| Company Name: |
BOC Sciences
|
| Tel: |
1-631-485-4226; 16314854226 |
| Email: |
info@bocsci.com |
| Products Intro: |
Product Name:Otelixizumab
CAS:881191-44-2
Remarks:Reach out to us for more information about custom solutions.
|
| Company Name: |
Shanghai YuanYe Biotechnology Co., Ltd.
|
| Tel: |
021-61312847; 18021002903 |
| Email: |
3008007409@qq.com |
| Products Intro: |
Product Name:Otelixizumab (anti-CD3)
CAS:881191-44-2
Purity:Purity>95% (SDS-PAGE&SEC); Endotoxin Level<1.0EU/mg; Human I Package:5mg Remarks:K10709
|
| Company Name: |
ShangHai Biochempartner Co.,Ltd
|
| Tel: |
177-54423994 17754423994 |
| Email: |
2853530910@QQ.com |
| Products Intro: |
Product Name:Otelixizumab
CAS:881191-44-2
Purity:95% Package:100ug;500ug;1mg
|
| Company Name: |
Guangzhou Hongyuan Chemical Co.,Ltd
|
| Tel: |
15817493340 |
| Email: |
981810490@qq.com |
| Products Intro: |
Product Name:Otelixizumab
CAS:881191-44-2
Purity:95% Package:1mg;1g;100g
|
|
| | Otelixizumab Basic information |
| Product Name: | Otelixizumab | | Synonyms: | Otelixizumab;Research Grade Otelixizumab(DHC27702);Otelixizumab (anti-CD3);Research Grade Otelixizumab | | CAS: | 881191-44-2 | | MF: | | | MW: | 0 | | EINECS: | | | Product Categories: | | | Mol File: | Mol File | ![Otelixizumab Structure]() |
| | Otelixizumab Chemical Properties |
| form | Liquid | | color | Colorless to light yellow |
| | Otelixizumab Usage And Synthesis |
| Uses | Otelixizumab (ChAglyCD3) is an anti-human CD3 monoclonal antibody and can be used for the research of type 1 diabetes[1]. | | in vivo | Otelixizumab (ChAglyCD3) (100 μg/mouse; i.v.; once) results in durable disease remission dependent on transferable T cell–mediated tolerance in diabetic transgenic mice[1]. | Animal Model: | BALB/c-huCD3e mice carrying the human CD3e chain[1] | | Dosage: | 100 μg/mouse | | Administration: | Intravenous injection, once | | Result: | Induced secretion of lower amounts of IL-6. Exhibited up-regulation of regulatory T cells. |
| | References | [1] Kuhn C, et al. Human CD3 transgenic mice: preclinical testing of antibodies promoting immune tolerance. Sci Transl Med. 2011 Feb 2;3(68):68ra10. DOI:10.1126/scitranslmed.3001830
[2] Guglielmi C, et al. Efficacy and safety of otelixizumab use in new-onset type 1 diabetes mellitus. Expert Opin Biol Ther. 2016 Jun;16(6):841-6. DOI:10.1080/14712598.2016.1180363 |
| | Otelixizumab Preparation Products And Raw materials |
|